Healthcare Industry News: Phadia
News Release - December 20, 2007
Aerocrine Enters Distribution Agreement with Phadia in FranceAerocrine AB (STO:AERO) announces that the company has entered into a distribution agreement with Phadia France.
SOLNA, Sweden--(HSMN NewsFeed)--Regulatory News: As of 1 January 2008, Aerocrine has granted Phadia the right to market and sell NIOX MINO® on the French market. Phadia, a world-leader within allergy diagnostics, already sells Aerocrine products in Spain.
In France about 4 million people have diagnosed asthma and the prevalence of asthma like symptoms is even higher, about 15%.
“Phadia has an established market position in France in addition to good knowledge of our products. We look forward to working together with Phadia to launch Aerocrine’s products in France,” says Paul de Potocki, CEO of Aerocrine.
“Through Phadia’s distribution of NIOX MINO in Spain, we have established a strong relationship with Aerocrine and have developed a good understanding of patient benefits from the company’s products. We are pleased to be entrusted with selling Aerocrine’s products in France as well,” says Magnus Lundberg, CEO of Phadia.
Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 10:00 AM on December 20, 2007.
Aerocrine AB is a clinically based medical technology corporation dedicated to improved asthma management and care. Aerocrine was listed on the Stockholm Stock Exchange on 15 June, 2007. The company is marketing NIOX® Flex on a worldwide basis and is also marketing NIOX MINO®, representing a new generation of hand-held devices, in Europe. Both products are tailored for rapid, non-invasive control of the inflammatory status in the airways and may play a critical role for optimized asthma care and disease control. Aerocrine is located in Sweden with wholly owned subsidiaries in the US, UK and Germany.
Phadia develops, manufactures and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. More than 3,000 laboratories in 60 countries use the company’s products. Supplying seven out of ten allergy laboratory tests worldwide, Phadia has remained the world leader in its field for more than 25 years. Phadia’s ImmunoCAP symptom profiles provide allergists, pediatricians and primary care physicians with precise, quantitative measurements of specific IgE levels, supporting the prognosis, diagnosis and follow-up of allergic patients.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.